Table 3.
Relative tumour burden quantified by fluorescence intensity in zebrafish embryonic models after treatment with TLD1433, delivered by three different administration routes. The fluorescence intensity is calculated as percentage, compared to the control dark group (100%).
| Cell Line | Route of TLD1433 Administration | Relative Tumour Burden as Measured by Fluorescence Intensity | |||||
|---|---|---|---|---|---|---|---|
| Ectopic Model | Orthotopic Model | ||||||
| Light Dose (J.cm−2) | PI | Light Dose (J.cm−2) | PI | ||||
| 0 | 114 | 0 | 114 | ||||
| CRMM1 | Water | 91% | 89% | 1.0 | 96% | 96% | 1.0 |
| Intravenous | 94% | 59% | 1.6 | 91% | 111% | 0.82 | |
| Retro-orbital | 85% | 53% | 1.6 | 120% | 65% | 1.8 | |
| CRMM2 | Water | 90% | 96% | 0.93 | 96% | 104% | 0.92 |
| Intravenous | 97% | 69% | 1.4 | 98% | 95% | 1.0 | |
| Retro-orbital | 93% | 60% | 1.6 | 100% | 45% | 2.2 | |